Objectives: To present a new standardized facial fat grafting technique.
Introduction: Injectable Tissue Replacement and Regeneration (ITR2) is a new, standardized method of fat grafting.
Materials / method: In performing ITR2 the first step is to diagnose the anatomic areas and tissues where volume loss has occurred by evaluating the surface topography of the face. Step two, addresses specific anatomic losses of these different tissues, including skin, facial fat in the deep and superficial compartments, and bone. Step three, replaces these anatomic losses with injectable autogenous or allogeneic fat grafts, de-cellurized bone and cartilage sized for structural replacement of bone and deep fat losses, superficial fat replacement and dermal and epithelial replacement and regeneration.
Results: Since 2015, all fat grafting patients underwent ITR2. ITR2 was performed alone under local or intravenous sedation; with resurfacing fractional lasers; and in patients having facelift or facial rejuvenation surgery. Complications occurred in 2 patients who required transcutaneous (n=1) or tranconjunctival (n=1) fat removal for excess noted in the lower eyelids. No instance of overgrowth has been seen to date with this anatomic approach. Improvement in skin texture and thickness has been noted up to two years after treatment.
Conclusion: Injectable Tissue Replacement and Regeneration is a new standardized means of fat grafting that addresses anatomic areas of skin, fat and bone loss. As newer techniques of injectable bone and cartilage gel are developed, losses in specific tissues can be addressed with “like” tissues, ushering in new approaches in injectable tissue engineering.
Disclosures
Did you receive any funding to support your research for this TOPIC?
No
Were you provided with any honoraria, payment or other compensation for your work on this study?
No
Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): Lipocube- royalties, shareholder; Tulip- royalties; Millennium Medical- royalties, shareholder
Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
Yes
Please specify date...: Patent pending, January 28, 2019
and status : ITR2 is trademarked
This work was not supported by any direct or non direct funding. It is under the author's own responsability